Top Page
Spire Healthcare
(LSE:SPI)
Spire Healthcare (SPI) vs. iShares MSCI United Kingdom ETF (EWC)
Spire Healthcare Business Overview & Revenue Model
Spire Healthcare Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.51B | 1.36B | 1.20B | 1.11B | 919.90M |
| Gross Profit | 683.60M | 520.60M | 440.50M | 394.10M | 361.80M |
| EBITDA | 250.40M | 231.20M | 202.10M | 182.20M | -51.90M |
| Net Income | 25.40M | 27.30M | 8.60M | -9.70M | -233.90M |
Balance Sheet | |||||
| Total Assets | 2.34B | 2.29B | 2.16B | 2.24B | 2.10B |
| Cash, Cash Equivalents and Short-Term Investments | 43.70M | 49.60M | 74.20M | 202.60M | 106.30M |
| Total Debt | 1.28B | 1.26B | 1.19B | 1.27B | 1.17B |
| Total Liabilities | 1.60B | 1.55B | 1.43B | 1.53B | 1.40B |
| Stockholders Equity | 748.40M | 739.90M | 731.00M | 709.60M | 706.60M |
Cash Flow | |||||
| Free Cash Flow | 123.60M | 115.50M | 72.80M | 101.30M | 95.10M |
| Operating Cash Flow | 235.70M | 199.90M | 160.50M | 170.60M | 141.70M |
| Investing Cash Flow | -99.00M | -157.20M | -98.00M | -48.30M | -46.40M |
| Financing Cash Flow | -145.10M | -82.90M | -190.90M | -26.00M | -79.80M |
Spire Healthcare Technical Analysis
Spire Healthcare Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | £784.43M | 67.23 | 4.50% | 1.29% | 6.74% | 54.83% | |
69 Neutral | £905.34M | 48.91 | 2.51% | 1.04% | 6.95% | -34.38% | |
64 Neutral | £443.45M | 62.08 | 2.93% | 1.27% | 40.66% | -55.09% | |
59 Neutral | $355.92M | ― | -5.04% | ― | -1.02% | 67.70% | |
55 Neutral | £316.12M | 8.17 | 11.74% | ― | 38.80% | ― | |
53 Neutral | $471.71K | ― | -3.66% | ― | -23.61% | -30.61% | |
51 Neutral | $7.46B | -0.16 | -46.00% | 2.25% | 22.82% | -2.28% |
Spire Healthcare Corporate Events
Spire Healthcare reported its interim results for the first half of 2025, showing a 4.9% revenue growth and a 2.8% increase in adjusted EBITDA, despite challenges such as National Insurance and Minimum Wage rises. The company has undergone significant transformation, including a reduction in staffing and consolidation of hospital functions, which is expected to yield over £20 million in savings in the second half of the year. Spire has also expanded its primary care services through acquisitions and new contracts, aiming to enhance its market position and operational efficiency. The company’s strategic initiatives and investments in technology are designed to support long-term growth and shareholder value, although the market remains dynamic and challenging.
The most recent analyst rating on (GB:SPI) stock is a Buy with a £310.00 price target. To see the full list of analyst forecasts on Spire Healthcare stock, see the GB:SPI Stock Forecast page.
Spire Healthcare Group plc has appointed Joh. Berenberg, Gossler & Co KG, London Branch as its Joint Corporate Broker alongside J.P. Morgan Securities plc, effective immediately. This strategic appointment is expected to enhance Spire Healthcare’s market positioning and strengthen its financial advisory capabilities, potentially benefiting its stakeholders and supporting its operational growth.
The most recent analyst rating on (GB:SPI) stock is a Buy with a £321.00 price target. To see the full list of analyst forecasts on Spire Healthcare stock, see the GB:SPI Stock Forecast page.
Spire Healthcare Group PLC has announced a change in major holdings, with Harwood Capital LLP acquiring or disposing of voting rights, resulting in a total of 3.076% voting rights in the company. This notification reflects changes in shareholder positions, potentially impacting the company’s governance and influencing its strategic decisions.
The most recent analyst rating on (GB:SPI) stock is a Buy with a £310.00 price target. To see the full list of analyst forecasts on Spire Healthcare stock, see the GB:SPI Stock Forecast page.
Spire Healthcare Group PLC announced that its Executive Directors, Justin Ash and Harbant Samra, have exercised their options under the 2022 Sharesave Plan, acquiring 1,818 shares each at an exercise price of £1.98 per share. This transaction reflects the directors’ continued confidence in the company’s growth and stability, as all acquired shares have been retained, potentially strengthening their alignment with shareholder interests.
The most recent analyst rating on (GB:SPI) stock is a Buy with a £2.90 price target. To see the full list of analyst forecasts on Spire Healthcare stock, see the GB:SPI Stock Forecast page.
Spire Healthcare Group PLC has announced a change in its voting rights, with Bridgemere Securities Limited increasing its stake to 5.5705% from a previous 4.0900%. This adjustment in voting rights could potentially impact the company’s governance and decision-making processes, influencing its strategic direction and stakeholder interests.
The most recent analyst rating on (GB:SPI) stock is a Buy with a £321.00 price target. To see the full list of analyst forecasts on Spire Healthcare stock, see the GB:SPI Stock Forecast page.
Spire Healthcare Group PLC has announced the grant of additional performance share awards under its Long Term Incentive Plan (LTIP) to Executive Director Harbant Samra. The awards, reflecting a recent change in his base salary, are set at 200% of his current salary and will vest based on performance conditions related to shareholder return, ROCE, hospital EBIT margin, and operational excellence. This move aligns with the company’s shareholder-approved Remuneration Policy and underscores its commitment to incentivizing leadership performance.
The most recent analyst rating on (GB:SPI) stock is a Buy with a £321.00 price target. To see the full list of analyst forecasts on Spire Healthcare stock, see the GB:SPI Stock Forecast page.
Spire Healthcare Group PLC has announced a change in its major holdings, with FIL Limited acquiring or disposing of voting rights and financial instruments. The transaction resulted in FIL Limited holding 9.105% of the voting rights in Spire Healthcare. This change in holdings could impact the company’s governance and influence decision-making processes, potentially affecting stakeholders and market perceptions.
The most recent analyst rating on (GB:SPI) stock is a Buy with a £321.00 price target. To see the full list of analyst forecasts on Spire Healthcare stock, see the GB:SPI Stock Forecast page.
Spire Healthcare Group PLC announced the successful passage of all resolutions at its 2025 Annual General Meeting, held on May 14, 2025. The results indicate strong shareholder support, with most resolutions receiving near-unanimous approval. This outcome reflects positively on the company’s governance and may enhance its position in the healthcare sector, potentially influencing investor confidence and future strategic decisions.
The most recent analyst rating on (GB:SPI) stock is a Buy with a £321.00 price target. To see the full list of analyst forecasts on Spire Healthcare stock, see the GB:SPI Stock Forecast page.
Spire Healthcare Group PLC reported that its performance from January to April 2025 aligned with expectations and the 2025 guidance, with a transformation program on track to deliver significant efficiencies. The company, which has full UK revenue exposure, does not foresee any major cost or supply chain issues due to recent tariff announcements. Additionally, Spire Healthcare has been named a founding supplier in the Government’s National Strategic Supplier Relationship programme, enhancing its collaboration with the NHS for sustainable NHS commissioning.
The most recent analyst rating on (GB:SPI) stock is a Buy with a £321.00 price target. To see the full list of analyst forecasts on Spire Healthcare stock, see the GB:SPI Stock Forecast page.